AngioDynamics Ownership
| ANGO Stock | USD 6.31 0.06 0.94% |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 40.2 M | Current Value 40.2 M | Avarage Shares Outstanding 29.8 M | Quarterly Volatility 9.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
AngioDynamics |
AngioDynamics Stock Ownership Analysis
About 91.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.17. Some equities with similar Price to Book (P/B) outperform the market in the long run. AngioDynamics has Price/Earnings To Growth (PEG) ratio of 1.87. The entity recorded a loss per share of 4.8. The firm had not issued any dividends in recent years. AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people. For more info on AngioDynamics please contact Joseph DeVivo at 518 795 1400 or go to https://www.angiodynamics.com.Besides selling stocks to institutional investors, AngioDynamics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AngioDynamics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AngioDynamics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AngioDynamics Quarterly Liabilities And Stockholders Equity |
|
AngioDynamics Insider Trades History
About 5.0% of AngioDynamics are currently held by insiders. Unlike AngioDynamics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AngioDynamics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AngioDynamics' insider trades
AngioDynamics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AngioDynamics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AngioDynamics backward and forwards among themselves. AngioDynamics' institutional investor refers to the entity that pools money to purchase AngioDynamics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2023-12-31 | 864.1 K | Armistice Capital, Llc | 2023-12-31 | 800 K | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 713.9 K | Jpmorgan Chase & Co | 2023-12-31 | 705.5 K | Aqr Capital Management Llc | 2023-12-31 | 694.2 K | Two Sigma Advisers, Llc | 2023-12-31 | 690.1 K | D. E. Shaw & Co Lp | 2023-09-30 | 686 K | Two Sigma Investments Llc | 2023-12-31 | 655.3 K | Exoduspoint Capital Management, Lp | 2023-12-31 | 629.6 K | Blackrock Inc | 2023-12-31 | 5 M | Vanguard Group Inc | 2023-12-31 | 2.3 M |
AngioDynamics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AngioDynamics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Helsel Dave a day ago Acquisition by Helsel Dave of 4371 shares of AngioDynamics subject to Rule 16b-3 | ||
Stephen Trowbridge over a month ago Acquisition by Stephen Trowbridge of 1927 shares of AngioDynamics at 4.67 subject to Rule 16b-3 | ||
Wallace Lynda M over three months ago Acquisition by Wallace Lynda M of 50000 shares of AngioDynamics subject to Rule 16b-3 | ||
Stephen Trowbridge over six months ago Exercise or conversion by Stephen Trowbridge of 8769 shares of AngioDynamics subject to Rule 16b-3 | ||
Stephen Trowbridge over six months ago Acquisition by Stephen Trowbridge of 28691 shares of AngioDynamics subject to Rule 16b-3 | ||
Stephen Trowbridge over six months ago Payment of 1362 shares by Stephen Trowbridge of AngioDynamics subject to Rule 16b-3 | ||
Stephen Trowbridge over a year ago Payment of 555 shares by Stephen Trowbridge of AngioDynamics subject to Rule 16b-3 |
AngioDynamics Corporate Filings
10Q | 9th of April 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 8th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 9th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with AngioDynamics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.Moving against AngioDynamics Stock
| 0.65 | NXGL | Nexgel Inc | PairCorr |
| 0.49 | ENSG | Ensign Group Financial Report 24th of April 2024 | PairCorr |
| 0.47 | COO | Cooper Companies Financial Report 6th of June 2024 | PairCorr |
| 0.47 | CVS | CVS Health Corp Financial Report 1st of May 2024 | PairCorr |
| 0.44 | POAI | Predictive Oncology | PairCorr |
The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.
The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for AngioDynamics Stock analysis
When running AngioDynamics' price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Revenue Per Share 8.105 | Quarterly Revenue Growth (0.07) | Return On Assets (0.05) | Return On Equity (0.62) |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.